Browse > Article
http://dx.doi.org/10.3904/kjim.2016.017

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity  

Chung, Woo-Baek (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
Youn, Ho-Joong (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
Publication Information
The Korean journal of internal medicine / v.31, no.4, 2016 , pp. 625-633 More about this Journal
Abstract
Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is difficult to recommend guidelines for the prevention or management of anthracycline-induced cardiotoxicity applicable to all cancer types. Therefore, anthracycline-induced cardiotoxicity remains a major limitation in the proper management of cancer patients treated with an anthracycline-combined regimen. Efforts have been extensive to determine the mechanism and treatment of anthracycline-induced cardiotoxicity. Because cardiotoxicity causes irreversible damage to the myocardium, prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops. This article will review the pathophysiological mechanisms of anthracycline-induced cardiotoxicity and strategies for protecting the myocardium from anthracycline.
Keywords
Cardiotoxicity; Anthracyclines; Doxorubicin; Drug therapy; Neoplasms;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Jung KW, Won YJ, Oh CM, et al. Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat 2015;47:142-148.   DOI
2 Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-2247.   DOI
3 Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.   DOI
4 Kim SM, Kwak CH, Lee B, et al. A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. Korean J Intern Med 2012;27:342-345.   DOI
5 Chung WB, Youn HJ, Choi YS, et al. The expression of cardiac ankyrin repeat protein in an animal model of adriamycin-induced cardiomyopathy. Korean Circ J 2008;38:455-461.   DOI
6 Levkau B, Schafers M, Wohlschlaeger J, et al. Survivin determines cardiac function by controlling total cardiomyocyte number. Circulation 2008;117:1583-1593.   DOI
7 Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879.   DOI
8 Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol 2008;21:978-989.   DOI
9 Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-399.   DOI
10 Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.   DOI
11 Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-1238.   DOI
12 Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013;31:3673-3680.   DOI
13 Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102-1111.   DOI
14 National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Internet]. Bethesda (MD): National Cancer Institute, c2009 [cited 2016 May 14]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
15 Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938-945.   DOI
16 Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxid Med Cell Longev 2015;2015:795602.
17 Chung WB, Yi JE, Jin JY, et al. Early cardiac function monitoring for detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer. J Breast Cancer 2013;16:178-183.   DOI
18 Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-1380.   DOI
19 Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-1988.   DOI
20 Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-1650.   DOI
21 Toro-Salazar OH, Ferranti J, Lorenzoni R, et al. Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2016;29:119-131.   DOI
22 Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii155-vii166.
23 Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63(25 Pt A):2751-2768.   DOI
24 Tarr A, Stoebe S, Tuennemann J, et al. Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy. Echo Res Pract 2015;2:81-88.   DOI
25 Poulin F, Thavendiranathan P. Cardiotoxicity due to chemotherapy: role of cardiac imaging. Curr Cardiol Rep 2015;17:564.
26 Tamene AM, Masri C, Konety SH. Cardiovascular MR imaging in cardio-oncology. Magn Reson Imaging Clin N Am 2015;23:105-116.   DOI
27 Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754.   DOI
28 Yu AF, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart 2016;102:425-430.   DOI
29 de Azambuja E, Ameye L, Diaz M, et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil-or epirubicin-based chemotherapy. Eur J Cancer 2015;51:2517-2524.   DOI
30 Park CS, Youn HJ, Cho EJ, et al. Cardioprotective effect of IGF-1 in mouse with adriamycin induced cardiomyopathy. Korean Circ J 2002;32:1116-1123.   DOI
31 Uhm JS, Chung WB, Yoon JS, Oh YS, Youn HJ. Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats. Clin Hypertens 2014;20:8.   DOI
32 Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol 2013;40:186-198.   DOI
33 Choi YS, Park CS, Cho EJ, et al. The relation between acute adriamycin induced cardiomyopathy and apoptosis in rat: study using 15 MHz high frequency transducer. J Korean Soc Echocardiogr 2002;10:35-43.   DOI
34 Corapcioglu F, Sarper N, Berk F, Sahin T, Zengin E, Demir H. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol 2006;23:71-80.   DOI
35 Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004;279:8290-8299.   DOI
36 Choi JY, Youn HJ, Kang JH, et al. Transthoracic echocardiographic assessment of adriamycin-induced cardiomyopathy in rats with a 15 MHz transducer. J Korean Soc Echocardiogr 2000;8:78-86.   DOI
37 Uhm JS, Youn HJ, Park CS, et al. Comparison of adriamycin-induced cardiomyopathy in normotensive rats and spontaneously hypertensive rats. J Korean Soc Hypertens J 2006;12:23-30.
38 Rochette L, Guenancia C, Gudjoncik A, et al. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 2015;36:326-348.   DOI
39 Salazar-Mendiguchia J, Gonzalez-Costello J, Roca J, Ariza-Sole A, Manito N, Cequier A. Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist. Arch Cardiol Mex 2014;84:218-223.
40 Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.   DOI
41 L'Ecuyer T, Sanjeev S, Thomas R, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 2006;291:H1273-H1280.   DOI
42 Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006;41:389-405.   DOI
43 Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213-1225.   DOI
44 Fu LX, Waagstein F, Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol 1990;29:15-20.   DOI
45 Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 2001;61:8422-8428.
46 Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007;21:413-427.   DOI
47 Chiosi E, Spina A, Sorrentino A, et al. Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. J Interferon Cytokine Res 2007;27:589-597.   DOI
48 Vejpongsa P, Yeh ET. Topoisomerase 2${\beta}$: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 2014;95:45-52.
49 Youn HJ, Kim HS, Jeon MH, et al. Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol Cell Biochem 2005;270:13-19.   DOI
50 Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-1642.   DOI